Candel Therapeutics (CADL) Treasury Shares (2022 - 2025)
Candel Therapeutics recorded quarterly Treasury Shares of $448000.0 in Q4 2025, little changed quarter-over-quarter from $448000.0 in Q3 2025, and little changed year-over-year from $448000.0 in Q4 2024.
Candel Therapeutics' Treasury Shares history runs 4 years deep, the most recent figure standing at $448000.0 for Q4 2025.
- In Q4 2025, Treasury Shares changed 0.0% year-over-year to $448000.0; the TTM figure through Dec 2025 stood at $448000.0 (changed 0.0% YoY), while the FY2025 annual figure was $448000.0, changed 0.0% from the prior year.
- Treasury Shares came in at -$122608.0 for Q3 2025 at Candel Therapeutics, down from $330779.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $448000.0 in Q2 2022 to a low of $448000.0 in Q2 2022.
- A 4-year average of $448000.0 and a median of $448000.0 in 2022 frame the typical range for Treasury Shares.
- On a YoY basis, Treasury Shares climbed as much as 399.45% in 2023 and fell as far as 120.02% in 2023.
- Candel Therapeutics' Treasury Shares stood at $448000.0 in 2022, then changed by 0.0% to $448000.0 in 2023, then changed by 0.0% to $448000.0 in 2024, then changed by 0.0% to $448000.0 in 2025.
- According to Business Quant data, Treasury Shares over the past three periods registered $448000.0, $448000.0, and $448000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 448,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 448,000.00 |
| Dec 31, 2025 | 448,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | -122,608.00 |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | -122,608.00 |
| Jun 30, 2025 | 448,000.00 |
| Jun 30, 2025 | 448,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Dec 31, 2024 | 330,779.00 |
| Dec 31, 2024 | 448,000.00 |
| Dec 31, 2024 | 448,000.00 |
| Dec 31, 2024 | 330,779.00 |
| Sep 30, 2024 | 448,000.00 |
| Sep 30, 2024 | -122,608.00 |
| Sep 30, 2024 | -122,608.00 |
| Sep 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | -122,608.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | -122,608.00 |
| Dec 31, 2023 | -122,608.00 |
| Dec 31, 2023 | 448,000.00 |
| Dec 31, 2023 | -122,608.00 |
| Dec 31, 2023 | 448,000.00 |
| Sep 30, 2023 | 612,366.00 |
| Sep 30, 2023 | 448,000.00 |
| Sep 30, 2023 | 448,000.00 |
| Sep 30, 2023 | 612,366.00 |
| Jun 30, 2023 | 448,000.00 |
| Jun 30, 2023 | 448,000.00 |
| Jun 30, 2023 | 612,366.00 |
| Jun 30, 2023 | 612,366.00 |
| Mar 31, 2023 | 612,366.00 |
| Mar 31, 2023 | 612,366.00 |
| Mar 31, 2023 | 448,000.00 |
| Mar 31, 2023 | 448,000.00 |
| Dec 31, 2022 | 612,366.00 |
| Dec 31, 2022 | 448,000.00 |
| Dec 31, 2022 | 448,000.00 |
| Dec 31, 2022 | 612,366.00 |
| Sep 30, 2022 | 448,000.00 |
| Sep 30, 2022 | 448,000.00 |
| Sep 30, 2022 | 122,608.00 |
| Sep 30, 2022 | 122,608.00 |
| Jun 30, 2022 | 122,608.00 |
| Jun 30, 2022 | 448,000.00 |
| Jun 30, 2022 | 448,000.00 |
| Jun 30, 2022 | 122,608.00 |